Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8835425 | 0.99 | MAPT (0.40) | MAPTUSP7PTGESCYP2C9TP53 | |
| SCHEMBL9164456 | 0.87 | PTGES (0.41) | MAPTPTGESSMN1; SMN2MEN1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4775543 | 0.83 | GRM2 (0.41) | MAPTCYP2C9SMN1; SMN2ALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL2248185 | 0.83 | NR4A2 (0.46) | MAPTCYP2C9SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL8835094 | 0.82 | GRM2 (0.41) | MAPTCYP2C9SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8835043 | 0.81 | NR4A2 (0.47) | MAPTCYP2C9SMN1; SMN2MEN1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL2248963 | 0.81 | SMN1; SMN2 (0.56) | MAPTPTGESSMN1; SMN2KMT2ADPP4 | |
| SCHEMBL9163362 | 0.80 | MAPT (0.52) | MAPTUSP7TP53SMN1; SMN2MEN1 | |
| SCHEMBL9162855 | 0.79 | HTR5A (0.41) | SMN1; SMN2CLK4 | |
| SCHEMBL27296771 | 0.79 | TP53 (0.39) | MAPTPTGESCYP2C9TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998972-B2 | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| EP-1509521-B1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-11-03 | — | — | US | disclosed |
| EP-1509521-A2 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | ABL1, PRKCA, PRKCQ | MAPT 1405/4885USP7 3406/4885PTGES 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.